Lightspeed to Participate in CIBC Eastern Institutional Investor Conference
Get Alerts LSPD Hot Sheet
Join SI Premium – FREE
MONTREAL, Sept. 12, 2019 /PRNewswire/ - Lightspeed POS Inc. ("Lightspeed" or the "Company") (TSX: LSPD), a leading provider of software, solutions and support systems to small and medium size retailers and restauranteurs, today announced that management will participate in CIBC's Eastern Institutional Investor Conference.

Event Details:
CIBC Eastern Institutional Investor ConferenceDate: Thursday, September 26, 2019Time: 1:30pm ETLocation: Montreal, Quebec
The presentation will be available via live audio webcast and archived replay on Lightspeed's investor relations website at www.investors.lightspeedhq.com.
About Lightspeed
Lightspeed (TSX: LSPD) is a cloud-based commerce platform powering small and medium-sized businesses in approximately 100 countries around the world. With smart, scalable, and dependable point of sale systems, it's an all-in-one solution that helps restaurants and retailers sell across channels, manage operations, engage with consumers, accept payments, and grow their business.
Headquartered in Montréal, Canada, Lightspeed is trusted by favorite local businesses, where the community goes to shop and dine. Lightspeed has grown to over 800 employees, with offices in Canada, USA, Europe, and Australia.
For more information, please visit: www.lightspeedhq.comOn social media: LinkedIn, Facebook, Instagram, YouTube, and Twitter
View original content to download multimedia:http://www.prnewswire.com/news-releases/lightspeed-to-participate-in-cibc-eastern-institutional-investor-conference-300917400.html
SOURCE Lightspeed POS Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CANADIAN SPACE AGENCY AND MDA SPACE CONCLUDE CONTRACT FOR REPLENISHMENT SATELLITE VALUED AT $688M
- Tata Elxsi and Sky Mark a Major Milestone in AI-led Autonomous Network Transformation with NEURON
- European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resect
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
CIBC, TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share